Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

Krystal Biotech is upgraded to Strong Buy as Vyjuvek sales surge and catalysts build. Click here to know more.

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...

Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...

CLASSIC enables large-scale testing of complex DNA circuits in human cells, advancing data-driven synthetic biology.

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today ...

Guanidine is an organic compound primarily used as a denaturing reagent to disrupt the structures of proteins and nucleic ...